A phase 1 clinical pharmacological study with a single oral dose of KAG-308
Latest Information Update: 07 May 2014
Price :
$35 *
At a glance
- Drugs KAG 308 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kaken Pharmaceutical
- 27 Mar 2014 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 02 Oct 2013 New trial record